Cargando…
Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
(1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese pat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865185/ https://www.ncbi.nlm.nih.gov/pubmed/36674306 http://dx.doi.org/10.3390/ijerph20021553 |
_version_ | 1784875773671243776 |
---|---|
author | Ferreira, Pedro L. Genrinho, Inês Santiago, Tânia Carones, Adriana Mazeda, Carolina Barcelos, Anabela Beirão, Tiago Costa, Flávio Santos, Inês Couto, Maura Rato, Maria Terroso, Georgina Monteiro, Paulo |
author_facet | Ferreira, Pedro L. Genrinho, Inês Santiago, Tânia Carones, Adriana Mazeda, Carolina Barcelos, Anabela Beirão, Tiago Costa, Flávio Santos, Inês Couto, Maura Rato, Maria Terroso, Georgina Monteiro, Paulo |
author_sort | Ferreira, Pedro L. |
collection | PubMed |
description | (1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese patients with SSc. (2) Methods: A multi-center study was conducted enrolling SSc patients. UCLA GIT 2.0 was validated in Portuguese using reliability (internal consistency, item –total correlation, and reproducibility) and validity (content, construct, and criterion) tests. Criterion tests included EQ-5D and SF-36v2. Social–demographic and clinical data were collected. (3) Results: 102 SSc patients were included, 82.4% of them female, and with a mean sample age of 57.0 ± 12.5 years old. The limited form of SSc was present in 62% of the patients and 56.9% had fewer than five years of disease duration. Almost 60% presented with SSc-GI involvement with a negative impact on quality of life. The means for SF-36v2 were 39.3 ± 10.3 in the physical component summary and 47.5 ± 12.1 in the mental component summary. Total GI score, reported as mild in 57.8% of the patients, was highly reliable (ICC = 0.912) and the Cronbach’s alpha was 0.954. There was a high correlation between the total GI score and EQ-5D-5L and SF-36v2 scores. (4) Conclusion: The Portuguese version of UCLA GIT 2.0 showed good psychometric properties and can be used in research and clinical practice. |
format | Online Article Text |
id | pubmed-9865185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98651852023-01-22 Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument Ferreira, Pedro L. Genrinho, Inês Santiago, Tânia Carones, Adriana Mazeda, Carolina Barcelos, Anabela Beirão, Tiago Costa, Flávio Santos, Inês Couto, Maura Rato, Maria Terroso, Georgina Monteiro, Paulo Int J Environ Res Public Health Article (1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese patients with SSc. (2) Methods: A multi-center study was conducted enrolling SSc patients. UCLA GIT 2.0 was validated in Portuguese using reliability (internal consistency, item –total correlation, and reproducibility) and validity (content, construct, and criterion) tests. Criterion tests included EQ-5D and SF-36v2. Social–demographic and clinical data were collected. (3) Results: 102 SSc patients were included, 82.4% of them female, and with a mean sample age of 57.0 ± 12.5 years old. The limited form of SSc was present in 62% of the patients and 56.9% had fewer than five years of disease duration. Almost 60% presented with SSc-GI involvement with a negative impact on quality of life. The means for SF-36v2 were 39.3 ± 10.3 in the physical component summary and 47.5 ± 12.1 in the mental component summary. Total GI score, reported as mild in 57.8% of the patients, was highly reliable (ICC = 0.912) and the Cronbach’s alpha was 0.954. There was a high correlation between the total GI score and EQ-5D-5L and SF-36v2 scores. (4) Conclusion: The Portuguese version of UCLA GIT 2.0 showed good psychometric properties and can be used in research and clinical practice. MDPI 2023-01-14 /pmc/articles/PMC9865185/ /pubmed/36674306 http://dx.doi.org/10.3390/ijerph20021553 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ferreira, Pedro L. Genrinho, Inês Santiago, Tânia Carones, Adriana Mazeda, Carolina Barcelos, Anabela Beirão, Tiago Costa, Flávio Santos, Inês Couto, Maura Rato, Maria Terroso, Georgina Monteiro, Paulo Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
title | Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
title_full | Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
title_fullStr | Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
title_full_unstemmed | Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
title_short | Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
title_sort | creation and validation of a portuguese version of the ucla scleroderma clinical trial consortium gastrointestinal tract instrument |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865185/ https://www.ncbi.nlm.nih.gov/pubmed/36674306 http://dx.doi.org/10.3390/ijerph20021553 |
work_keys_str_mv | AT ferreirapedrol creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT genrinhoines creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT santiagotania creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT caronesadriana creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT mazedacarolina creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT barcelosanabela creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT beiraotiago creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT costaflavio creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT santosines creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT coutomaura creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT ratomaria creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT terrosogeorgina creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument AT monteiropaulo creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument |